The New England Journal of Medicine reported phase 3 trial details regarding the company's peanut allergy treatment for toddlers.
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...
The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.
The company can now move forward with a late-stage study of its lead pipeline candidate.
March S&P 500 futures (ESH23) are trending up +0.17% this morning after three major U.S. benchmark indices closed sharply lower on Thursday, with the technology-heavy Nasdaq dropping the most after stronger-than-expected...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT). Such investors...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT). Such investors...
DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA. Stock declines.
Montrouge, France, August 1, 2022 DBV Technologies Reports Second Quarter 2022 Financial Results DBV closes Q2 with a cash balance of $248M following...
AMF REGULATED INFORMATIONMontrouge, France, July 27, 2022 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies...